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Background and Purpose—Focal cerebral arteriopathy (FCA)—a common cause of arterial ischemic stroke in previously 
healthy children—often progresses over days to weeks, increasing the risk of recurrent stroke. We developed a novel 
severity scoring system designed to quantify FCA progression and correlate with clinical outcomes.
Methods—The VIPS study (Vascular Effects of Infection in Pediatric Stroke) prospectively enrolled 355 children with 
arterial ischemic stroke (2010–2014), including 41 with centrally confirmed FCA. Two neuroradiologists independently 
reviewed FCA cerebrovascular imaging, assigning a graded severity score of zero (no involvement) to 4 (occlusion) 
to individual arterial segments. The FCA severity score (FCASS) was the unweighted sum. In an iterative process, we 
modeled scores derived from different combinations of arterial segments to identify the model that optimized correlation 
with clinical outcome, simplicity, and reliability.
Results—The optimal FCASS summed scores from 5 arterial segments: supraclinoid internal carotid artery, A1, A2, M1, 
and M2. The median (interquartile range) baseline FCASS was 4 (2–6). Of 33 children with follow-up imaging, the 
maximum FCASS (at any time point) was 7 (5–9). Twenty-four (73%) had FCA progression on follow-up with their 
maximum FCASS at a median of 8 (5–35.5) days poststroke; their median FCASS increase was 4 (2.5–6). FCASS did 
not correlate with recurrent arterial ischemic stroke. Maximum (but not baseline) FCASS correlated with 1-year pediatric 
stroke outcome measures (P=0.037).
Conclusions—Our novel scoring system for FCA severity correlates with neurological outcomes in the VIPS cohort 
and provides a tool for FCA treatment trials under development.   (Stroke. 2018;49:2590-2596. DOI: 10.1161/
STROKEAHA.118.021556.)
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Focal cerebral arteriopathy (FCA) of childhood, also known as transient cerebral arteriopathy, is an acute, 
monophasic disease causing unilateral stenosis of the intra-
cranial cerebral arteries, mainly involving the anterior circu-
lation. One of the most common causes of arterial ischemic 
stroke (AIS) in a previously healthy child, FCA, has also been 
described in young adults.1–4 It confers a high risk of recur-
rent stroke (≤25% within 1 year), compounding poststroke 
lifelong disability.5,6 Most cases are presumed to be inflam-
matory; vessel wall imaging demonstrates enhancement of 
affected arterial segments.7 In its early phase, FCA can rap-
idly progress over days to weeks. Children with progressive 
arteriopathies have a higher risk of recurrent ischemia,6,8,9 and 
a single study suggests a link between elevated inflammatory 
biomarkers (hsCRP [high-sensitivity C-reactive protein] and 
SAA [serum amyloid A]), arteriopathy progression, and stroke 
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recurrence.8 Varicella zoster virus (VZV) is a long-established 
cause of FCA,10–12 yet other pathogens, including other herpes 
viruses, likely play a role as FCA continues to occur in VZV-
vaccinated children.13
Corticosteroids are increasingly used to treat FCA, al-
though in the absence of clinical trial data.14,15 Equipoise 
remains: steroids might suppress the presumed focal inflam-
matory process but might also worsen the underlying infec-
tious pathogenesis. A Delphi consensus identified this issue 
as the highest priority for a clinical trial in the field of child-
hood stroke.16 Investigators currently developing FCA treat-
ment trial protocols have realized the need for a quantitative 
measure of FCA severity to serve as a clinical trial surrogate 
end point and quantify temporal evolution of the arteriopathy. 
Using the subcohort of children with FCA enrolled in the VIPS 
study (Vascular Effects of Infection in Pediatric Stroke), our 
goals were (1) to develop an FCA severity score (FCASS) that 
correlates with clinical outcomes and (2) to apply the score 
to describe the natural history of FCA. We also performed 
exploratory analyses to determine whether the final FCASS 
correlated with previously reported VIPS study biomarkers of 
inflammation and infection.8,17
Methods
In accordance with the National Institutes of Health-approved data 
sharing policy for the VIPS study, the data supporting this study are 
available from the corresponding author on request. The VIPS study 
was a prospective cohort study that enrolled 355 children (29 days to 
18 years of age) with AIS at 37 international centers and collected 
clinical and imaging data and serum samples.2,4 Ethics approval was 
obtained by the institutional review board at each center, and writ-
ten informed consent was obtained for each enrollment. We centrally 
reviewed clinical data and all clinically obtained cerebral and vascular 
imaging to confirm the AIS diagnosis, estimate the infarct volume 
(using ABC/2), and classify cervical and cerebral arteriopathies.2,4 A 
board-certified neuroradiologist (M.W.) delineated the infarct contour 
and the brain contour on fluid-attenuated inversion recovery (FLAIR) 
images and, taking into account FLAIR slice thickness, calculated 
the absolute infarct volume and brain volume. We then calculated the 
relative infarct volume (percentage of total brain volume) by dividing 
the absolute volume of the infarct by the absolute volume of the brain. 
As reported previously, we defined FCA as “unifocal and unilateral 
stenosis/irregularity of the large intracranial arteries of the anterior 
circulation (distal internal carotid artery [ICA] and/or its proximal 
branches),” and then subclassified as FCA inflammation type, FCA 
dissection type, and undetermined FCA.4
Development of FCASS
For the current study, we designed an initial FCASS based on the 
vascular imaging appearance of 9 unilateral arterial segments: cer-
vical, petrous, cavernous, and supraclinoid segments of the ICA; M1 
and M2 segments of the middle cerebral artery; A1 and A2 segments 
of the anterior cerebral artery; and the posterior cerebral artery (ei-
ther P1 or P2). Because FCA is a unilateral disease, we measured 
only the involved (symptomatic) side of the intracranial circulation. 
Two neuroradiologists (M.W. and N.S.) independently reexamined 
the vascular imaging for all 41 FCA cases in VIPS and applied the 
initial scoring system. Each segment was assigned a graded severity 
score: 0, no involvement; 1, irregularity or banding with no stenosis; 
2, stenosis <50% reduction in diameter; 3, stenosis >50% reduction 
in diameter; and 4, occlusion. The small size of M2 and A2 branches 
precluded reliable scoring of stenosis severity, so any stenosis of 
those segments was initially scored as 3 (with no option to score 
as 2); hence, these segments were classified into 1 of only 4 cat-
egories (scored 0, 1, 3, or 4). The scores for the individual arterial 
segments were summed without weighting to provide an initial total 
score. These methods would not capture changes over time that were 
within scoring categories (eg, for progression from 60% to 90% ste-
nosis; both would be coded as 3). Hence, we devised the delta point: 
a single point that could be added/subtracted to indicate any interval 
worsening (+1) or improvement (−1) not otherwise captured by the 
sum total of the scored segments (only a single delta point could 
be applied, regardless of whether a single segment or multiple seg-
ments changed). We defined the maximum FCASS for each case as 
the highest total score at any time point. If only a single FCASS 
score was available (n=8), that score was also considered to be the 
maximum, unless otherwise indicated. One neuroradiologist (M.W.) 
scored all imaging twice in 2 separate sessions.
Optimization of the FCASS
We then optimized the scoring system with the a priori goals of 
maximizing correlation with clinical outcomes while maintaining 
simplicity (user-friendliness) and achieving a high degree of intra-
rater and interrater reliability. Clinical outcomes included 1-year 
cumulative stroke recurrence rates, as defined previously,5 and 
1-year pediatric stroke outcome measures (PSOM). The PSOM is 
a validated outcome measure for childhood AIS, which quantifies 
neurological exam findings and can be estimated via a telephone pa-
rental questionnaire; scores range from 0 (no deficits) to 10 (pro-
found deficits).18,19 The VIPS study performed 1-year PSOMs (12±3 
months poststroke) in clinic for the majority and via telephone when 
in-clinic assessments were not feasible.20
In an iterative process, we created different FCASS models by 
serially removing arterial segments (Methods in the online-only 
Data Supplement). We assessed each individual model, measuring 
the correlation of the FCASS (baseline and maximum scores) with 
clinical outcomes and determining intrarater and interrater relia-
bility. . We carried forward the optimal FCASS model to the final 
refinement step: determining whether it was possible to further col-
lapse the numeric scoring system (0–4, for each arterial segment) 
into fewer categories. Instructions for the final (optimal) FCASS 
system are in Methods in the online-only Data Supplement. We then 
analyzed the final FCASS in our cohort to describe its correlation 
with serum biomarkers and, in those with follow-up imaging, its ev-
olution over time.
Data Analysis
We computed intraclass correlation coefficients as estimates of 
intrarater and interrater reliability for the total FCASS and indi-
vidual components using standard regression methods. We utilized 
Spearman rank-order correlation to assess for correlation between 
FCASS and relative infarct volume. In analyses of correlation with 
clinical outcomes, our predictor variables included both baseline 
and maximum FCASS, both including and excluding those without 
follow-up data. Using methods previously described for the VIPS 
cohort, we used Cox proportional hazards models to measure risk 
of stroke recurrence in children with FCA5 and Spearman correla-
tion coefficients to measure potential association with 1-year PSOM 
scores.20 Because our specific purpose was to compare multiple 
models to find the one that best correlated with our chosen outcomes 
(rather than testing a particular hypothesis), we made no multiple 
comparison adjustments.
In exploratory analyses, we calculated Spearman correla-
tion coefficients between FCASS (baseline and maximum) and 
the inflammatory and infectious biomarkers previously measured 
and reported in the VIPS cohort. Inflammatory markers included 
serum concentrations of hsCRP, SAA, MPO (myeloperoxidase), 
and TNF-α (tumor necrosis factor-α).8 Infectious biomarkers in-
cluded serum IgM/IgG antibodies for herpes simplex virus 1 and 2, 
Cytomegalovirus, Epstein-Barr virus, and VZV.17 We used our previ-
ously published algorithm for using acute and convalescent serolo-
gies to classify serological evidence of acute herpesvirus infection 
as a dichotomous variable;17 we used Wilcoxon rank sum tests to 
compare FCASS scores in those with versus without infection. All 
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analyses were done using Stata v14 (Stata Corp, College Station, 
TX) with α set at 0.05.
Results
The 41 FCA cases in the VIPS cohort (25 FCA inflammation 
type, 7 FCA dissection type, and 9 undetermined FCA) had a 
median age of 11.3 years (interquartile range [IQR] 7.4–14.3 
years; range, 5 months to 17.7 years) and were 46% men. The 
overall VIPS cohort had a median age of 7.2 (IQR, 2.8–14.3) 
years and was 56% men. FCA cases were racially diverse: 27 
(66%) white, 4 (10%) Asian, 3 (7%) Hispanic, 2 (5%) black, 
and 5 (12%) other/unknown. Baseline vascular imaging was 
performed on the same day as the stroke in 41% of cases: 
median of 1 day (IQR, 0–2 days; range 0–14 days) after the 
stroke ictus. Magnetic resonance angiogram was the most 
common imaging modality, performed in 38 cases (93%) at 
baseline and 40 cases (98%) overall (including follow-up im-
aging); conventional angiography was performed in 14 (34%) 
and computed tomography angiogram in 15 (37%). At base-
line, the median absolute infarct volume was 14.7 mL (IQR, 
6.5–33.0 mL; range, 0.08–251 mL); the median relative infarct 
volume was 1.1% (IQR, 0.5%–2.3%; range, 0.005%–15.2 %).
Development of the FCASS
Because we identified no posterior cerebral artery abnor-
malities, we excluded this segment from the model. Only 
34 cases (83%) had cervical vascular imaging (at any time 
point), and 25 (73%) of these had no cervical arterial involve-
ment; we, therefore, also excluded the cervical ICA from the 
model. Model A included all the remaining segments (pet-
rous, cavernous, and supraclinoid segments of the ICA; M1, 
M2, A1, and A2), which were then removed in an iterative 
fashion (models B–E). We modeled both baseline and max-
imum FCASS; for this analysis, the baseline score of those 
with no follow-up imaging was also defined as the maximum 
score. Interrater and intrarater reliability was high for all mod-
els (Table I in the online-only Data Supplement). None of the 
models correlated with recurrent stroke (Table 1). In all mod-
els, the maximum FCASS score was more closely associated 
with 1-year PSOMs than the baseline score; model B (supra-
clinoid ICA, M1, M2, A1, and A2 segments) for the maximum 
FCASS score was the only model that demonstrated a signifi-
cant correlation with 1-year PSOMs (Table 1). Model B was, 
therefore, carried forward to the final refinement step of maxi-
mizing simplicity. We created additional models collapsing 
the numeric scoring system (0–4) into fewer categories: model 
B1 combining scores 1 through 4, model B2 combining scores 
1 and 2 and scores 3 and 4, and model B3 combining scores 1 
through 3. Each of these models demonstrated a weaker cor-
relation with 1-year PSOMs (Table II in the online-only Data 
Supplement). Hence, we designated model B with the initial 
numeric scoring system (0–4, for each arterial segment) as 
the final (optimal) FCASS (Methods in the online-only Data 
Supplement). We used this model for all subsequent analyses.
Change in FCASS Over Time
The baseline FCASS was a median of 4 (IQR, 2–6; range, 
1–15; Figure 1). Of the 41 cases, 33 (80%) had at least 1 fol-
low-up vascular imaging study, and 28 (68%) had >1. Those 
with versus without follow-up vascular imaging had sim-
ilar absolute and relative infarct volumes, baseline FCASS 
scores, and 1-year PSOMs (Table III in the online-only 
Data Supplement). The median time from stroke to first fol-
low-up imaging was 10 days (IQR, 5–52; range, 1–405) and 
from stroke to last follow-up was 112 days (IQR, 4–349; 
range, 0–674 days). The change in FCASS is summarized in 
Figure 1; representative imaging is shown in Figure 2. Our 
imaging reviewers did not apply the delta point for any case 
in this cohort. The maximum FCASS among all 41 cases, in-
cluding those with a single assessment, was a median of 7 
(IQR, 4–9; range, 1–16); the maximum FCASS among those 
33 cases with follow-up vascular imaging was similar (me-
dian, 7; IQR, 5–9; range, 2–16). Among those 33 with mul-
tiple FCASS measurements, the score increased (indicating 
worsening arteriopathy) in 24 (73%), remained unchanged in 
8 (24%), and decreased (without an initial increase) in 1 (3%). 
Among the 24 with increased scores, the median change was 
+4 (IQR, 2.5–6; range, 1–9), and the median time from stroke 
Table 1. Clinical Outcome Correlation of Iterative Models of the FCASS
Model Arterial Segments Excluded*





HR 95% CI P Value‡ HR 95% CI P Value‡
A None excluded 0.13 1.1 0.97–1.14 0.19 0.19 1.05 0.97–1.13 0.24
B Proximal (petrous/cavernous) ICA§ 0.037 1.1 0.91–1.23 0.47 0.037 1.05 0.90–1.24 0.53
C Proximal ICA, A1 0.089 1.10 0.92–1.32 0.30 0.12 1.10 0.91–1.34 0.32
D Proximal ICA, A1, A2 0.087 1.1 0.92–1.35 0.26 0.14 1.10 0.91–1.34 0.34
E Proximal ICA, A1, A2, M2 0.11 1.2 0.89–1.59 0.25 0.21 1.18 0.86–1.61 0.31
Data for maximum FCASS are shown. Model A includes petrous, cavernous, and supraclinoid segments of the ICA; M1 and M2 segments of the MCA; and A1 and A2 
segments of the ACA. Subsequent models exclude arterial segments in an iterative fashion. ACA indicates anterior cerebral artery; AIS, arterial ischemic stroke; FCA, 
focal cerebral arteriopathy; FCASS, focal cerebral arteriopathy severity score; HR, hazard ratio; ICA, internal carotid artery; MCA, middle cerebral artery; PCA, posterior 
cerebral artery; and PSOM, pediatric stroke outcome measures.
*PCA was normal in all cases and not included in any model.
†P values for trend test for correlation between maximum FCASS and 1-y PSOM categorical variable.
‡Cox proportional hazards for correlation between maximum FCASS and time to first recurrent AIS.
§Final (optimal) model.
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to the imaging with the maximum FCASS was 8 days (IQR, 
5–35.5; range, 2–189). The greatest change observed was in 
a case of FCA dissection type: baseline score of 7 and a max-
imum score of 16, 2 days later. Of 19 patients with their last 
follow-up imaging ≥6 months after the stroke, the last FCASS 
was a median of 4 (IQR, 0–7; range, 0–15); 26% of patients 
had complete normalization of their vascular imaging (final 
FCASS of 0; Figure 1).
Correlation With Infarct Volume 
and Neurological Outcomes
Larger relative infarct volumes on baseline imaging correlated 
with higher FCASS scores: Spearman ρ, 0.41 (P=0.008) for 
baseline FCASS (Figure 3) and 0.50 (P=0.0008) for max-
imum FCASS. Children with (n=8) versus without (n=33) re-
current AIS during the study period had similar FCASS scores 
(Table 2). The median 1-year PSOM in our cohort (n=39 with 
1-year outcomes) was 1 (IQR, 0–1.5; range, 0–4.5). Higher 
1-year PSOMs (indicating greater neurological deficits) cor-
related with higher maximum FCASS scores (P=0.037; 
Table 2).
Correlation With Inflammatory Biomarkers 
and Herpesvirus Exposure
Acute serum samples were collected for 38 children at a me-
dian of 5 days poststroke (IQR, 3–10 days); 25 had convales-
cent serum samples collected at median 20 days poststroke 
(IQR, 14–32 days). Baseline and maximum FCASS scores 
(utilizing all subjects, including those without follow-up 
imaging) correlated with acute serum levels of hsCRP but 
not other levels of inflammatory biomarkers (Table 3). The 
median (IQR) hsCRP was 0.86 (0.48–1.56) for the quartile 
with the highest maximum FCASS scores, compared with 
0.16 (0.16–0.25) for the lowest quartile. FCASS did not dif-
fer significantly by serological evidence of acute herpesvirus 
infection. Of 25 FCA cases with paired (acute and convales-
cent) serologies, 10 (40%) had evidence of an acute herpes-
virus infection: 8 positive for herpes simplex virus (1 or 2) 
alone, 1 positive for VZV, and 1 positive for herpes simplex 
virus and VZV. The median (IQR) baseline FCASS was 5 
(1–6) for the 10 herpes-positive cases and 3 (2–7) for the 
15 herpes-negative cases (P=0.98); maximum FCASS was 
8 (6–12) for herpes-positive and 6 (2–8) for herpes-negative 
cases (P=0.13).
Discussion
By developing a novel tool for quantifying the severity, extent, 
and evolution of arterial disease in children with FCA—the 
Figure 1. Box and whisker plots summarizing baseline, maximum, 
and final focal cerebral arteriopathy severity score (FCASS) scores. 
Maximum FCASS includes only those with follow-up imaging (n=33). 
Final FCASS includes only those 19 cases with follow-up imaging ≥6 
mo poststroke (box represents interquartile range [IQR], line within 
box represents median, whiskers represent upper adjacent [75th 
percentile+1.5×IQR] and lower adjacent [25th percentile−1.5×IQR] 
values, and dots represent outliers).
Figure 2. Cerebral magnetic resonance angiogram images demonstrating evolution of a typical case of focal cerebral arteriopathy inflammation type: axial 
views (top) and frontal views (bottom) at 4 time points. Baseline images demonstrate mild irregularity of the right supraclinoid internal carotid artery and M1 
segment of the middle cerebral artery. The 2-mo images show progression to severe stenosis; the 4- and 8-mo images demonstrate subsequent improve-
ment. FCASS, focal cerebral arteriopathy severity score
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FCASS, we demonstrated a wide range of disease severity 
within our FCA cohort and found dynamic changes over 
time with doubling of the score during a matter of days in the 
most severely progressive cases. Children with higher max-
imum FCASS scores had significantly larger infarct volumes 
and worse neurological outcomes at 1 year. FCASS severity 
also correlated with 1 acute serum inflammatory biomarker, 
hsCRP, providing some additional evidence that FCA is an in-
flammatory disease. We could not confirm an association with 
evidence of acute herpesvirus infection, however.
Two published studies describe severity scores for child-
hood arteriopathies, although neither was specific to FCA.9,21 
Both examined the correlation with recurrent stroke. The cere-
brovascular stenosis score used a similar quantitative scoring 
system (1 for low-grade stenosis, 2 for high-grade stenosis, 
or 3 for occlusion), scoring 18 bilateral arterial segments and 
summing the individual scores.21 When applied to a cohort 
of 49 children with AIS and a variety of arteriopathies, the 
cerebrovascular stenosis score demonstrated good interrater 
reliability (intraclass correlation coefficient, 0.77; 95% CI, 
Figure 3. Scatter plot demonstrating the corre-
lation between baseline focal cerebral arteriopa-
thy severity score (FCASS) and relative infarct 
volume (percentage of total brain volume), also 
measured at baseline.




n Median Range n Median Range n Median Range
Overall 41 4 1–15 33 7 2–16 19 4 0–15
Subtype‡
  FCAi 25 3 1–8 22 6 2–13 12 3.5 0–7
  FCAd 7 10 5–13 5 14 5–16 3 5 0–9
  FCAu 9 3 1–15 6 8 2–15 4 3.5 0–15
Recurrent stroke
  Yes 8 4.5 1–8 8 7 3–16 4 4.5 0–9
  No 33 4 1–15 25 7 2–16 15 4 0–15
1-y PSOM§
  0–1 (no/mild deficits) 25 4 1–15 21 6 2–15 13 3 0–15
  1.5–3 (moderate) 12 5 1–13 9 9 3–16 5 7 1–9
  3.5–6 (severe) 2 7 2–12 2 12 8–16 1 5 5–5
  6.5–10 (profound) 0 … … 0 … … 0 … …
FCAd indicates focal cerebral arteriopathy dissection type; FCAi, focal cerebral arteriopathy inflammation type; FCASS, focal cerebral 
arteriopathy severity score; FCAu, focal cerebral arteriopathy undetermined; IQR, interquartile range; and PSOM, pediatric stroke outcome 
measures.
*Time from index stroke to imaging with maximum FCASS: median, 5 d (range, 0–189 days; IQR, 2–15); includes all of those with follow-
up (n=33), with or without progression.
†The last FCASS score for those cases with follow-up imaging ≥6 mo poststroke.
§PSOM missing for 2 cases; trend test for correlation, P=0.68 for baseline, P=0.037 for maximum, and P=0.16 for final FCASS score.
‡Differences between FCAi and FCAd are significant for baseline (P=0.001) and maximum (P=0.0007) but not for final FCASS (P=0.11).
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0.63–0.87), although lower than that for FCASS (0.86; 95% 
CI, 0.81–0.90); cerebrovascular stenosis score intrarater relia-
bility was not assessed. Higher cerebrovascular stenosis score 
predicted stroke recurrence amongst children with moyamoya 
but not other forms of arteriopathy. A British study of 43 chil-
dren with AIS and abnormal magnetic resonance angiogram 
categorized the magnetic resonance angiogram abnormalities 
into 3 grades without scoring individual arterial segments; 
the authors did not assess intrarater or interrater reliability.9 
Although limited by variable timing of follow-up vascular im-
aging, they found that children with progressive arteriopathies 
(of any subtype) had triple the risk of recurrent ischemic events 
(stroke, transient ischemic attack, or silent infarcts) compared 
with those without evidence of arteriopathy progression.
In our overall VIPS cohort, including all types of cervical 
and cerebral arteriopathy (eg, FCA, moyamoya, cervical dis-
section, and genetic arteriopathies), we similarly found that 
arteriopathy progression predicted recurrent AIS.8 In the FCA 
subcohort, however, FCASS scores did not predict recurrence, 
although higher maximum FCASS scores correlated with 
both larger infarct size and poorer 1-year neurological out-
comes. We speculate that this finding may reflect the nature 
of progressive brain injury in children with accelerating FCA. 
Because FCA is a focal disease, its progression may result 
in expansion of the core infarct in the same ICA distribution 
and a slow worsening of the original deficits (eg, worsened 
hemiparesis) that may not be distinct enough from the index 
stroke to meet criteria for a recurrent stroke. However, we did 
not have adequate follow-up brain imaging to measure infarct 
expansion and test this hypothesis.
Limitations include our small sample size; we may have 
been underpowered to detect an association between FCASS 
and stroke recurrence, for example. Our cohort had only clin-
ically obtained imaging, hence combining a mix of imaging 
modalities and variable performance and timing of follow-up 
imaging. The FCASS was developed primarily using magnetic 
resonance angiogram, which can overestimate arterial ste-
nosis relative to conventional angiography and computed to-
mography angiogram; we were unable to study how different 
modalities may yield different results. The clinical decision 
to perform follow-up imaging at a particular time may itself 
reflect greater severity of the disease or worse clinical out-
comes (we may have been underpowered to detect a differ-
ence between those with and without follow-up imaging). We 
may have missed periods of arteriopathy progression, leading 
to misclassification of cases with versus without progression. 
Future studies would be improved by imaging collection at 
systematic time points among all patients. We developed the 
tool in a single patient cohort; however, a validation study is 
now underway, testing FCASS in an independent FCA cohort 
from the Swiss Neuropaediatric Stroke Study.22
Despite these limitations, the FCASS demonstrated high 
intrarater and interrater reliability and correlated with neu-
rological outcomes in the VIPS cohort. After validation in 
an independent cohort, we anticipate it could serve as a clin-
ically meaningful measurement and end point for FCA treat-
ment trials. Our natural history data provide further evidence 
that FCA is a dynamic arteriopathy. Frequent progression 
in the first days to weeks suggests a window for therapeutic 
intervention to improve neurological outcomes. The recent 
Swiss/Australian observational study of FCA found that chil-
dren who received corticosteroid therapy had better 6-month 
PSOMs than those who did not14; this compelling finding 
should now be tested in clinical trials.
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Baseline FCASS Maximum FCASS
n=36 n=36†
Spearman ρ P Value Spearman ρ P Value
hsCRP 0.35 0.036 0.47 0.004
MPO 0.30 0.08 0.28 0.10
SAA 0.20 0.24 0.27 0.11
TNF-α −0.05 0.75 −0.16 0.34
FCA indicates focal cerebral arteriopathy; FCASS, focal cerebral 
arteriopathy severity score; hsCRP, high-sensitivity C-reactive protein; MPO, 
myeloperoxidase; SAA, serum amyloid A; and TNF-α, tumor necrosis factor-α.
*Inflammatory markers were not available for 5 of the 41 patients with FCA.
†For those with no follow-up imaging, the baseline score was considered 
to be the maximum score.
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